Component

Human ELAVL4 / HuD RNA-binding protein

Human ELAVL4 / HuD RNA-binding protein

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. The HuD study and author follow-up identify RA among compounds showing STD-NMR evidence of HuD binding.

    Rosmarinic acid → Human ELAVL4 / HuD RNA-binding protein Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Indexed primary abstract only; author follow-up identifies RA among prior binding hits. Full 2021 text unavailable.; Primary author follow-up Introduction passages describing the previous HuD binding study; new folic-acid cell findings are not RA findings.
    experimental_model
    Virtual screening followed by STD-NMR; authors identify four hits.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Rosmarinic acid collection; exact intervention and molecular form govern interpretation. · Rosmarinic acid
    plain_language
    The HuD study and author follow-up identify RA among compounds showing STD-NMR evidence of HuD binding.
    primary_references
    Identification of Compounds Targeting HuD. Another Brick in the Wall of Neurodegenerative Disease Treatment. | https://pubmed.ncbi.nlm.nih.gov/34219450/ | https://doi.org/10.1021/acs.jmedchem.1c00191
    primary_references
    Short- and Long-Term Regulation of HuD: A Molecular Switch Mediated by Folic Acid? | https://pubmed.ncbi.nlm.nih.gov/37569576/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10418318/ | https://doi.org/10.3390/ijms241512201
    source_locator
    Reviewed reference ra-hud-binding; Binding is not functional inhibition. Folic-acid follow-up cell results are not RA results; RA clinical neuronal benefit remains untested.

    Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026) · lines 481–488

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Virtual screening followed by STD-NMR; authors identify four hits. · Recorded from source · Recorded from source

    ### ra-hud-binding The HuD study and author follow-up identify RA among compounds showing STD-NMR evidence of HuD binding. Binding is not functional inhibition. Folic-acid follow-up cell results are not RA results; RA clinical neuronal benefit remains untested. Model and exposure: Virtual screening followed by STD-NMR; authors identify four hits. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Identification of Compounds Targeting HuD. Another Brick in the Wall of Neurodegenerative Disease Treatment. | 2021 | https://pubmed.ncbi.nlm.nih.gov/34219450/ | https://doi.org/10.1021/acs.jmedchem.1c00191 | Access: Indexed primary abstract only; author follow-up identifies RA among prior binding hits. Full 2021 text unavailable. Reference: Short- and Long-Term Regulation of HuD: A Molecular Switch Mediated by Folic Acid? | 2023 | https://pubmed.ncbi.nlm.nih.gov/37569576/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10418318/ | https://doi.org/10.3390/ijms241512201 | Access: Primary author follow-up Introduction passages describing the previous HuD binding study; new folic-acid cell findings are not RA findings.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.